Thus, the lack of IRF8 and IRF4 expression is likely to be critically involved in the pathogenesis of human CML, and seeking a way to restore the expression and function of these IRFs could be a powerful new approach to the improvement of CML therapy. This evidence concerns the gene IRF8 and chronic myelogenous leukemia, BCR-ABL1 positive.